HEALTHY LIFESTYLE




Aluminium hydroxide
Aluminium hydroxide.JPG

Aluminium hydroxide

CLINICAL USE

  • Phosphate binding agent
  • Antacid

    DOSE IN NORMAL RENAL FUNCTION

  • Phosphate binder: 4–20 capsules daily in divided doses
  • Antacid: 1 capsule 4 times daily and at bedtime

    PHARMACOKINETICS

  • Molecular weight                           : 78
  • %Protein binding                           : 70–90
  • %Excreted unchanged in urine     : No data
  • Volume of distribution (L/kg)       : No data
  • half-life – normal/ESRD (hrs)      : No data

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                : Unknown dialysability. Dose as in normal renal function
  • HD                     : Unknown dialysability. Dose as in normal renal function
  • HDF/high flux   : Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD      : Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs None known

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

  • K/DOQI guidelines caution that CKD 5 patients on chronic therapy may develop aluminium toxicity; therefore best avoided in all but short-term therapy (calcium carbonate, calcium acetate, lanthanum or sevelamer are used in chronic therapy)
  • Take/administer with or immediately before meals
  • In patients undergoing chronic therapy with aluminium hydroxide, serum aluminium levels should be monitored
  • other drugs